SureTrader SureTrader
Home > Boards > US OTC > Miscellaneous >

InMed Pharmaceuticals Inc. (IMLFF)

IMLFF RSS Feed
Add IMLFF Price Alert      Hide Sticky   Hide Intro
Moderator: lesgetrich
Search This Board:
Last Post: 9/26/2016 11:26:16 AM - Followers: 65 - Board type: Free - Posts Today: 0




And so it begins...

NEWS RELEASE

Cannabis Technologies Commences trading on CSE

Vancouver, BC May 21, 2014 Cannabis Technologies Inc. (CSE: CAN) is pleased to announce that it has completed the acquisition of BSI Sciences (see NR dated May 16, 2014) and has commenced trading on the Canadian Stock Exchange under the new symbol “CAN”.

The Company will pay a finder's fee with respect to the acquisition of the shares of BSI Sciences. The finder's fee is payable to an individual and complies with the policies of the CSE.

About Cannabis Technologies (“CTI”)

CTI is a biopharmaceutical drug discovery and development company uniquely focused on the therapeutic potential of cannabinoids. The company consists of two divisions:

Drug Discovery & Development – CTI is utilizing its proprietary “Cannabinoid Drug Design Platform” to identify new bioactive compounds within the marijuana plant that interact with certain gene responsible for specific diseases. CTI’s extensive research and intellectual properties will initially be focused on the development of several new cannabinoid based treatments for glaucoma, cancer & angiogenesis, Inflammation and pain.

Cultivation & Breeding – CTI’s botanical research division has begun the research & development into the individual strains and clones that will produce the raw material bases for future pharmaceutical research. To comply with the demands of the Pharmaceutical industry, a phytopharmaceutical feedstock must meet high expectations regarding the minimum and maximum content of a range of compounds. Cultivation techniques and pharmaceutical levels of exacting chemical consistency are critical for all applications to regulatory authorities. OFFICAIL 

OFFICAL WEBSITE : http://www.cannabis-tech.com/s/corporate.asp

And so it continues.....

NEWS REALEASE 

Cannabis Technologies Commences Trading on OTCQB

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 4, 2014) - Cannabis Technologies Inc. (CSE:CAN)(OTCQB:CANLF) announces that as of June 04, 2014, its common stock will begin trading on OTC Markets Group's OTCQB venture stage marketplace ("OTCQB") under the symbol "CANLF".

OTCQB offers investors transparent trading in early-stage and developing U.S. and international companies. To be eligible, companies must meet a minimum $0.01 bid test, be current in their reporting and undergo an annual verification and management certification process. International companies must also be listed on a qualified foreign stock exchange and receive a Letter of Introduction from a Principal American Liaison ("PAL"), which must be a qualified third-party investment bank, securities law firm or depositary bank. U.S. investors can find current financial disclosures and Real-Time Level 2 quotes for Cannabis Technologies on www.otcmarkets.com.

For further information regarding OTCQB, please visit www.otcmarkets.com.

About Cannabis Technologies ("CTI")

CTI is a biopharmaceutical drug discovery and development company uniquely focused on the pharmacology and therapeutic potential of cannabinoids.

CTI is utilizing its proprietary "Cannabinoid Drug Design Platform" to identify new bioactive compounds within the marijuana plant that interact with certain gene responsible for specific disease.

Our extensive research and intellectual properties will initially be focused on the development of several new cannabinoid based treatments for Ocular, Cancer & Angiogenesis, and Inflammation, Pain.

46 Reasons why Cannabis Technologies (CAN) will Succeed: Read more at http://www.stockhouse.com/companies/bullboard/c.can/cannabis-technologies-inc#LC4guMpHGMd0E4JA.99

http://www.stockhouse.com/companies/bullboard/c.can/cannabis-technologies-inc?postid=22781425

Corporate Overview

Cannabis Technologies (CTI) is a biopharmaceutical company that specializes in developing cannabis-based botanical and non-botanical therapies through the Research and Development into the extensive pharmacology of Cannabinoids.

CTI is utilizing its proprietary "Cannabinoid Drug Design Platform" to identify new bioactive compounds within the marijuana plant that interact with certain gene responsible for specific diseases. 

Our extensive research and intellectual properties will initially be focused on the development of several new cannabinoid based treatments for Ocular, Cancer & Angiogenesis, and Inflammation, Pain.
 

Management

Craig Schneider, B.A.

President & CEO
Mr. Schneider has over 20 years of extensive experience in Capital market financing, business development & strategic planning with public companies in Technology, Biotechnology and the Resource sector. He was a Co-founder of Magnum Uranium, a TSX.V company which was purchased by TSX Listed Energy Fuels (TSX: EFR). Mr. Schneider is a founder of Cannabis Technologies Inc. and has been instrumental in building the company to its current stage of development.

Dr. Sazzad Hossain, Ph.D., M.Sc.

Chief Scientific Officer
Dr. Hossain has more than 20 years of academic and industrial experience in new drug discovery, natural health product development. He was Group Leader and Senior Scientist at Biotechnology Research Institute of National Research Council Canada, Government of Canada's prime biotechnology research organization where he set up pharmacology laboratory to evaluate safety and efficacy of new drugs under development in the areas of cancer, cardiovascular and ocular diseases. Prior to joining the National Research Council Canada, he was at Xenon Pharmaceuticals in Vancouver, B.C, where was Associate Director of Pharmacology and led pharmacology teams targeting pain, inflammation and cardiovascular diseases. Dr. Hossain received his PhD in Biology from Moscow State Academy of Veterinary Medicine & Biotechnology and received post-doctoral training in the Department of Nutritional Science and Department of Medical Genetics of University of British Columbia. He was associate professor of pharmacology at Federal University of Minas Gerais, Brazil between 1988 -1996. He is the author of more than 40 peer-reviewed papers, primarily in the pharmacology, genetics and nutritional sciences.

Dr. Hyder A. Khoja, Ph.D., M.Sc., A.Ag.

Director of Botanical Research and Cultivation
Dr. Hyder Ali Khoja is highly growth focused individual with 17 years of extensive experience in a broad range of life sciences and business services with strong leadership combined with functional expertise and experience in general business management. He was serving as a Senior Agri. Research & Development Scientist for Advanced Nutrients, Ltd.

He brings in a strong adaptive ability in leading diverse regulatory program areas, and solid experience both in science and policy domains. His industry experience spans from initiation, operation, and contribution towards developing several research and business proposals in the fields of Agriculture-Food Security, Food Safety & Sovereignty, Alternative energy, Renewable resources, Biofuels, Nutraceutical, Hydroponics, Agriculture & Land use management and Technology transfer. Prior to joining the Advanced Nutrients Ltd, he held multiple positions in USA where he dealt business and research operations. While working at the Center of Excellence for Hazardous Materials Management, NM-USA, he built a foundation of strong cross-functional skills including marketing, finance, business development, and operations with successful Algae for Energy (biofuel project) grant from US-Department of Energy for over US $23 million. Dr. Khoja holds his Ph.D., in Cellular & Molecular Biology and M.Sc., in Plant Biotechnology and Physiology from the Institute National Polytechnique (Ecole National Supérieure Agronomique de Toulouse, France; and Sindh Agriculture University, TandoJam-Pakistan respectively. He received his post-doctoral training from Michigan State University-DOE Plant Research Laboratory. In his past tenure he served as a Research Faculties at Virginia Tech, University of Wyoming, and Texas Tech Health Sci. Center He has presented his work both in at federal government and academic institutions with authorship in over 18 peer-reviewed papers, primarily in genomics, plant physiology, and alternative energy. His work was also recognized and appeared in United Nations Food and Agriculture Organization (FAO) Environment and Natural Resources Management as a working paper for Algae-based Biofuels

Terese Giesleman

Chief Financial Officer
Terese has had 23 years' experience with public companies listed on the TSX, TSXV, OTCBB, NASDAQ and AMEX, in the roles of Chief Financial Officer, Treasurer, and Corporate Secretary. Terese has accumulated an extensive background in corporate and financial reporting and compliance for Canada and the United States, including particularly relevant experience in financings, treasury, international corporate structures and financial reporting.
 

Board of Directors

Craig Schneider

Director
Mr. Schneider has over 20 years of extensive experience in Capital market financing business development & strategic planning with public companies in Technology, Biotechnology and the Resource sector. He was also a Co-founder of Magnum Uranium, a TSX.V company which was purchased by TSX Listed Energy Fuels (TSX: EFR). Mr. Schneider is a founder of Cannabis Technologies Inc. and has been instrumental in building the company to its current stage of development.

Stephen Tong

Director
Stephen Tong was educated at the University of British Columbia where he received his B.A. in 1992, and at the University of Manitoba where he received his LL.B. in 1998. Stephen was called to the Bar of British Columbia in 1999.

Stephen practices corporate and securities law, acting for both public and private companies in a variety of industry sectors including mining, oil and gas, industrial and biotechnology. Stephen's most recent biotechnology deal involves a client working in research at the University of British Columbia, who has developed a potentially ground-breaking drug which may cure Alzheimer's disease. The deal involved protecting the client's intellectual property, incorporating, corporate finance and governance, and taking the drug through toxicity trials and FDA approval. At present the client is exploring exit strategies.

The bulk of Stephen's practice focuses on financings including initial public offerings and private placements, public listings, reverse takeovers and changes of business, corporate restructuring, mergers and acquisitions, corporate governance and continuous disclosure matters. In addition, Stephen sits on the Board of Directors of several private and public companies and performs various in-house counsel roles.

Scientific Advisory Board

Dr. Tarek S. Mansour, Ph.D., M.Sc.

Scientific Advisor
Dr. Tarek Mansour, Ph.D., is a veteran executive of the Life Science sector with over 26 years of experience in drug discovery and development. He has held senior leadership and management positions within both the biotechnology and pharmaceutical sector.

Dr. Mansour's industrial career started in 1989 with BioChem Pharma in Quebec; after which he joined Wyeth-Ayerst in 1997 as Assistant Vice-President to direct the medicinal chemistry efforts at the site in Pearl River, NY. In 2009, his responsibilities were expanded to head the Chemical Sciences Department at four discovery sites in the USA, as well as CRO support in India. After the Wyeth acquisition by Pfizer in 2009, Dr. Mansour was responsible for transition of staff and projects to the Pfizer pipeline. Subsequently, in 2010 he became the Executive Vice-President of R&D for Xenon Pharmaceuticals in British Columbia, Canada until early 2013. In mid-2013, Dr. Mansour became the Founder and Chief Executive Officer of Sabila Biosciences LLC, New York.

Dr. Mansour's expertise spans multiple therapeutic areas including anti-infectives, oncology, inflammatory, metabolic, cardiovascular and pain. Under his leadership, several compounds have progressed to various stages of clinical evaluation including FDA approvals and late stage development. Amongst these candidates are Epivir, Zeffix, Troxatyl, Bosulif, Neratinib and PFE384.

Dr. Mansour received a B.S. degree in Chemistry from the American University of Beirut, Lebanon (1977), M.Sc. in Chemistry from the University of Manchester Institute of Science and Technology, U.K. (1979), a Ph.D. degree from the University of Missouri-Columbia, U.S.A. (1982) and a diploma in Applied Management from McGill University, Canada (1993). Following postdoctoral tenure at the University of Ottawa, Dr. Mansour moved to McGill University in 1985 as a research associate in the Immunomedicinal Chemistry Chair.

 

Platform Technology

Our proprietary Cannabinoid Drug Design Platform ("CDP") allows bioinformatics tools to identify individual chemical compounds from the cannabis plant which can be targeted to develop therapies for specific diseases and conditions. 

This Platform Technology, coupled with our highly capable team, will enable the Company to discover therapies based on scientifically proven genomics and metabolomics both quickly and effectively.  
 

Pipeline



CTI-085

Is a topical formulation containing a proprietary compound of cannabinoids and non-cannabis based active ingredients for the treatment of Glaucoma. Cannabis Technologies has identified our lead composition (CTI 085) through 12 months of discovery and preclinical studies that showed efficacy in lowering intraocular pressure (IOP) in animal models. Cannabinoids have IOP lowering effects, thus, they have therapeutic potential in the treatment of glaucoma. Our objective for this therapy was to develop a safer; cannabis based topical anti-glaucoma formulation without systemic side effects. 
 

Therapeutic Area of Focus

Proposed Targets to Develop Drugs From Cannabis and Other Botanical Sources

Ocular Diseases

  • Glaucoma

     

Inflammation/Pain/Arthritis

Orphan Disease

  • Huntington's
    Epilepsy

     

Metabolic Disease

  • Diabetes
    Obesity

     

Cancer & Angiogenesis

 

Cannabis Compounds & Their Targeted Disease Areas


Cannabis Compounds & their targeted disease areas

 
 

Platform Technology

Our proprietary Cannabinoid Drug Design Platform ("CDP") allows bioinformatics tools to identify individual chemical compounds from the cannabis plant which can be targeted to develop therapies for specific diseases and conditions. 

This Platform Technology, coupled with our highly capable team, will enable the Company to discover therapies based on scientifically proven genomics and metabolomics both quickly and effectively.
 

Cannabinoid Science

The majority of pharmaceutical and academic research & development being performed with cannabis revolves around the understanding of its active ingredients, the Cannabinoids


Currently there are between 80-100 cannabinoids that have been isolated from cannabis, that affect the body's cannabinoid receptors and are responsible for unique pharmacological effects.

There are three general types of cannabinoids: herbal cannabinoids which occur uniquely in the cannabis; endogenous cannabinoids produced in the bodies of humans and animals and synthetic cannabinoids produced in the laboratory.
 

Cannabinoid Receptors


Before the 1980s, it was often speculated that cannabinoids produced their effects through nonspecific interaction with cell membranes, instead of interacting with specific receptors. The discovery of the first cannabinoid receptors in the 1980s helped to resolve this debate. These receptors are common in animals, and have been found in mammals, birds, fish and reptiles. There are currently two known types of cannabinoid receptors, called CB1 and CB2.

CB1 receptors are found primarily in the brain, specifically in the basal ganglia and in the limbic system, including the hippocampus. They are also found in the cerebellum and in both male and female reproductive systems. CB1 receptors are essentially absent in the absent in the medulla oblongata, the part of the brain that is responsible for respiratory and cardiovascular functions. Thus, there is not a risk of respiratory or cardiovascular failure as there is with many other drugs. CB1 receptors appear to be responsible for the euphoric and anticonvulsive effects of cannabis.

CB2 receptors are almost exclusively found in the immune system, with the greatest density in the spleen. CB2 receptors appear to be responsible for the anti-inflammatory and possible other therapeutic effects of cannabis.

The protein sequences of these two receptors are about 45% similar. In addition, minor variations in each receptor have been identified. There is some indication that other receptors exist, but none have been confirmed. Cannabinoids bind reversibly and stereo-selectively to the cannabinoid receptors. The affinity of an individual cannabinoid to each receptor determines the effect of that cannabinoid. Cannabinoids that bind more selectively to certain receptors are more desirable for medical usage.
 

Herbal Cannabinoids


Herbal cannabinoids are nearly insoluble in water but soluble in lipids, alcohols and other non-polar organic solvent. All herbal cannabinoids are derived from their respective 2-carboxylic acids (2-COOH) by decarboxylation that is, catalyzed by heat, light, or alkaline conditions. Herbal cannabinoids occur naturally only in the cannabis plant, and are concentrated in a viscous resin that is produced in glandular structures known as trichcomes. In addition to cannabinoids, the resin is rich in terpenes , which are largely responsible for the odor of the cannabis plant.

There are over sixty known herbal cannabinoids. Of these, tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabinol (CBN) are the most prevalent and have received the most study. Other common ones are listed below:
 
CBG Cannabigerol
CBC Cannabichromene
CBL Cannabicyclol
CBV Canabivarol
THCV Tetrahydrocannabivarin
CBDV Cannabidivarin
CBCV Cannabichromevarin
CBGV Cannabigerovarin
CBGM Cannabigerol Monoethyl Ether


THC is the primary psychoactive component of the plant. Medically, it appears to mediate pain and to be neuroprotective. THC has a greater affinity for the CB1 receptor than for the CB2 receptors. Its effects are perceived to be more cerebral.

CBD is not psychoactive, and appears to mediate the euphoric effect of THC. It may decrease the rate of THC clearance from the body, perhaps by interfering with the metabolism of THC in the liver. Medically, it appears to relieve convulsion, inflammation, anxiety, and nausea. CBD has a greater affinity for the CB2 receptor than for the CB1 receptor. It is perceived to have more effect on the body.

CBN is the primary product of THC degradation, and there is usually little of it in a fresh plant. CBN content increases as THC degrades in storage, and with exposure to light and air. It is only mildly psychoactive, and is perceived to be sedative or stupefying.

These compounds may be in different forms depending on the position of the double bond in the alicyclic carbon ring. There is potential for confusion because there are different numbering systems used to describe the position of this double bond. The dibenzopyran numbering system is most widely used today. Under this system, the major form of THC is called delta-9-THC, while the minor form is called delta-8-THC. Under the alternate terpene numbering system, these same compounds are called delta-1-THC and delta-6-THC, respectively.

Most herbal cannabinoid compounds are 21 carbon compounds. However, some do not follow this rule, primarily because of variation in the length of the side chain attached to the aromatic ring. In THC, CBD, and CBN, this side chain is a pentyl (5 carbon) chain. In the most common homologue, the pentyl chain is replaced with a propyl (3 carbon) chain. Cannabinoids with the propyl side chain are named using the suffix "varin", and are designated, for example, THCV, CBDV, or CBNV. It appears that shorter chains increase the intensity and decrease the duration of the activity of the chemicals.

Cannabinoids were first discovered in the 1940s, when CBD and CBN were identified. The structure of THC was first determined in 1964. Due to molecular similarity and ease of synthetic conversion, it was originally believed that CBD was a natural precursor to THC. However, it is now known that CBD and THC are produced independently in the cannabis plant. Cannabinoid production starts when an enzyme causes geranyl-pyrophosphate and olivetolic acid to combine and form CBG. Next, CBG is independently converted to THC, CBD or CBC, each of which is formed by action of a separate synthase enzyme. For the propyl homologues (THCV, CBDV and CBNV), there is a similar pathway that is based on CBGV.

Cannabis plants can exhibit wide variation in the quantity and type of cannabinoids they produce. The mixture of cannabinoids produced by a plant is known as the plant's cannabinoid profile. Selective Breeding has been used to control the genetics of plants and modify the cannabinoid profile. For example, strains of hemp, which are used as fiber, are bred such that they are low in psychoactive chemicals like THC. Strains used in medicine are often bred for high CBD content, and strains used for recreational purposes are usually bred for high THC content, or for a specific chemical balance. Some strains of more than 20% THC have been created.

Quantitative analysis of a plant's cannabinoid profile is usually determined by gas chromatography (GC), or more reliably by gas chromatography combined with mass spectroscopy (GC/MS). Liquid chromatography (LC) techniques are also possible, although these are often only semi-quantitative or qualitative. There have been systematic attempts to monitor the cannabinoid profile of cannabis over time, but their accuracy is impeded by the illegal status of the plant in many countries.

Cannabinoids can be administered by; smoking, vaporizing, oral ingestion, transdermal patch, intravenous injection, sublingual absorption, or rectal suppository. Once in the body, most cannabinoids are metabolized in the liver, , although some is stored in fat. Delta-9-THC is metabolized to 11-hydroxy-delta-9-THC, which is then metabolized to 9-carboxy-THC. Some cannabis metabolites can be detected in the body after several weeks.

Cannabinoids can be separated from the plant by extraction with organic solvents. Hydrocarbona and alcohols are often used as solvents. However, these solvents are flammable and many are toxic. Supercritical solvent extraction with carbon dioxide is an alternative technique. Although this process requires high pressures, there is minimal risk of fire or toxicity, solvent removal is simple and efficient, and extract quality can be well controlled. Once extracted, cannabinoid blends can be separated into individual components using wiped film vacuum distillation or other distillation techniques. However, to produce high purity cannabinoid chemical synthesis or semisynthesis is generally required.
 

Breeding & Cultivation

CTI's botanical research team has begun to develop the individual strains & clones that will produce the raw material bases for future pharmaceutical research.


To comply with the demands of the pharmaceutical industry, and in marked contrast to illicit cannabis, a phytopharmaceutical feedstock must meet high expectations regarding the minimum and maximum content of a range of compounds.

Cultivation techniques and pharmaceutical levels of exacting chemical consistency are critical for all applications to regulatory authorities. CTI will be implementing and following an exacting set of environmental and scientific controls.

CTI will take advantage of Strain differences to develop drugs for specific diseases. 

This heavily involves studying plant development and secondary metabolite biosynthesis in both indoor and outdoor conditions and thus could lead to the commercial production of an increasing range of phyto-pharmaceuticals.

Specific studies need to be performed to ascertain how growing methods affect the secondary metabolite content. They will also be aimed to find out how a tight specification can be met while satisfying commercial and environmental expectations

The main active ingredients in this are the cannabinoids THC and CBD, but other pharmacologically active cannabinoids are also present and are being investigated

CTI will take advantage of Strain differences to develop drugs for specific diseases. 
 

Breeding Program of Plant Growth & Evaluation

Breeding Program of Plant Growth & Evaluation

 

Investors
 

Share Structure

 
Share Structure (as of Fri May 16, 2014)
Issued & Outstanding 40,849,285
Warrants 2,760,000
Options 1,700,000
Fully-Diluted 45,309,285


 

Press Releases

July 16, 2014  Cannabis Technologies Announces Momentum PR
http://www.cannabis-tech.com/s/news-releases.asp?ReportID=664869&_Type=Press-Releases&_Title=Cannabis-Technologies-Announces-Momentum-PR
June 24, 2014  Cannabis Technologies Announces Glaucoma Therapy Entering into Phase 1 Clinical Trials
http://www.cannabis-tech.com/s/news-releases.asp?ReportID=660882&_Type=Press-Releases&_Title=Cannabis-Technologies-Announces-Glaucoma-Therapy-Entering-into-Phase-1-Clin...
June 10, 2014  Cannabis Technologies Appoints Dr. Tarek S. Mansour, Ph.D. to Scientific Advisory Board
http://www.cannabis-tech.com/s/news-releases.asp?ReportID=657990&_Type=Press-Releases&_Title=Cannabis-Technologies-Appoints-Dr.-Tarek-S.-Mansour-Ph.D.-to-Scientific-Adv...
June 04, 2014  Cannabis Technologies Commences Trading on OTCQB
http://www.cannabis-tech.com/s/news-releases.asp?ReportID=656867&_Type=Press-Releases&_Title=Cannabis-Technologies-Commences-Trading-on-OTCQB
May 21, 2014  Cannabis Technologies Commences trading on CSE
http://www.cannabis-tech.com/s/news-releases.asp?ReportID=654504&_Type=Press-Releases&_Title=Cannabis-Technologies-Commences-trading-on-CSE
May 20, 2014  Cannabis Technologies Inc. to List on CSE
http://www.cannabis-tech.com/s/news-releases.asp?ReportID=654316&_Type=Press-Releases&_Title=Cannabis-Technologies-Inc.-to-List-on-CSE
May 16, 2014  Meridex Announces Agreement to Acquire Biogen Sciences Inc.
http://www.cannabis-tech.com/s/news-releases.asp?ReportID=653494&_Type=Press-Releases&_Title=Meridex-Announces-Agreement-to-Acquire-Biogen-Sciences-Inc.


Presentations
 

Corporate Presentation - June 2014


http://www.cannabis-tech.com/i/pdf/presentations/Presentation-201406v2.pdf

Events
 

Date Details
 
June 28th - July 1, 2014 2014 International Cannabinoid Society Conference 
Baveno , Italy
 
June 28- July 1, 2014 Cannabis Investor Conference 
Denver, Colorado

 
 

Subscribe
http://www.cannabis-tech.com/s/subscribe.asp

Media

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IMLFF
Current Price
Volume:
Bid Ask Day's Range
SureTrader
IMLFF News: InMed Engages Peter Mountford as Strategic Advisor 05/05/2015 04:00:00 AM
IMLFF News: InMed Pharmaceuticals Qualifies for Electronic Trading in the U.S. 04/30/2015 11:00:00 AM
IMLFF News: InMed Awarded Grant for Proprietary Nanoparticle-Based Delivery System for Glaucoma Therapy 04/15/2015 06:00:00 AM
IMLFF News: InMed Receives Exemption Status from Health Canada 03/23/2015 08:00:00 AM
IMLFF News: InMed Forms Strategic Collaboration to Develop Novel Phytocannabinoid Therapies for Ocular Allergies 03/10/2015 11:00:00 AM
PostSubject
#1187   How did the presentation go? Any updates? ericzfw 09/26/16 11:26:16 AM
#1186   Our newest board member is good too. He's bigideaportugal 09/20/16 02:58:51 PM
#1185   I'm a bit puzzled too. However there are lesgetrich 09/20/16 11:29:34 AM
#1184   This is crazy now. you don't have volumn ibetrading 09/19/16 04:38:34 PM
#1183   Very touching and heart wrenching film. Makes you lesgetrich 09/18/16 01:04:05 PM
#1182   Nice piece, but it doesn't tell us much lesgetrich 09/18/16 12:32:17 PM
#1181   Epidermolysis Bullosa rosie10 09/18/16 09:51:43 AM
#1180   Chris Parry's Inmed analysis release Sept 15, 2016 rosie10 09/18/16 09:34:21 AM
#1179   We're overdue for a progress report on clinical trials. lesgetrich 09/17/16 01:26:20 PM
#1178   Lots of volume today.... bigideaportugal 09/16/16 04:52:36 PM
#1177   Lots of volume today.... bigideaportugal 09/16/16 04:52:30 PM
#1176   Maybe we'll get some news from the conference today. lesgetrich 09/13/16 09:18:19 AM
#1175   ...and... www.otcmarkets.com/stock/IMLFF/news/InMed-Appoints-Andrew-Hull lesgetrich 09/13/16 09:15:58 AM
#1174   Something's up at InMed... lesgetrich 09/13/16 09:12:11 AM
#1173   We need something here!!!! Trial news,,,, something??? bigideaportugal 09/07/16 10:19:01 PM
#1172   Uranus blindjohn 08/09/16 01:29:16 AM
#1171   It shows Inmed is alive and still functioning lesgetrich 07/31/16 03:09:39 PM
#1170   is this good?? bigideaportugal 07/30/16 10:07:08 PM
#1169   InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$304,500 rosie10 07/28/16 04:51:46 PM
#1168   The price is ridiculous‚Ķ.it's so undervalued it's embarassing... Momendumb 07/19/16 10:19:12 AM
#1167   Good results and this could pick up and wingtrade 07/15/16 02:53:00 PM
#1166   We should be getting some clinical trial results soon. lesgetrich 07/15/16 02:20:32 PM
#1165   $IMLFF entered here $.06 - huge potential here wingtrade 07/15/16 12:49:07 PM
#1164   June 16, 2016 09:02 ET rosie10 06/16/16 03:48:29 PM
#1163   2016-06-13 10:16 ET - News Release rosie10 06/13/16 11:37:18 AM
#1162   Hopefully this is a good sign of things ibetrading 06/09/16 10:08:04 AM
#1161   3 new filings on cse by inmed- hope? SamL67 06/08/16 09:36:39 AM
#1160   Office is shared with another company the directors Aliquot 06/06/16 11:48:57 AM
#1159   I think Chris Bogart's email response "when would inmedfooledme 05/30/16 02:24:45 PM
#1158   ...and??? what did he say?? Bing420 05/30/16 08:05:09 AM
#1157   Would love to know what he says. Bing420 05/20/16 12:27:29 PM
#1156   I contacted the new CEO Chris Bogart. He bigideaportugal 05/20/16 12:56:18 AM
#1155   They've at least verified that the company is lesgetrich 05/18/16 04:40:41 PM
#1154   Yes, seems to me it will be very Aliquot 05/18/16 01:12:21 PM
#1153   Clinical trials in 2016? See updated corporate presentation--has SamL67 05/18/16 01:06:30 PM
#1152   Ok, well they can't answer the phone or Aliquot 05/18/16 11:28:22 AM
#1151   May 18, 2016 rosie10 05/18/16 10:21:08 AM
#1150   Yep, glad you noticed it...192,165 shares traded... Entendance 05/11/16 09:27:09 AM
#1149   Again showning premarket trade--191k shares at .22 SamL67 05/11/16 09:15:45 AM
#1148   Interesting! Perhaps someone knows something we don't :-) lesgetrich 05/10/16 02:18:23 PM
#1147   3 different Trading Platforms report these trades and Entendance 05/10/16 12:11:44 PM
#1146   I don't see it on Quotestream. Normally penny lesgetrich 05/10/16 11:51:26 AM
#1145   I think its a glitch--yahoo finance had the SamL67 05/10/16 11:33:20 AM
#1144   Today 101,981 shares from 8.00 a.m to 9:10:23 a.m. Entendance 05/10/16 11:01:42 AM
#1143   Private placements perhaps? lesgetrich 05/10/16 10:58:02 AM
#1142   Second day on IMLFF level II with strange Entendance 05/10/16 08:17:44 AM
#1141   I have also tried to contact then with Aliquot 05/06/16 11:24:41 AM
#1140   It's no surprise that they don't have a lesgetrich 05/05/16 04:32:45 PM
#1139   May, 5th 2016 Paul Brennan will be leaving inmedfooledme 05/05/16 03:14:09 PM
#1138   Paul Brennan was brought in at a $220,000 inmedfooledme 05/05/16 03:04:21 PM
PostSubject